Core Viewpoint - AgomAb Therapeutics has made its debut on the US stock market with an IPO price of $16, experiencing an opening drop of over 13% [1] Company Overview - AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative disease-modifying therapies for immune and inflammatory diseases [1] - The company's initial strategy targets chronic fibrotic indications with high unmet medical needs, specifically through the inhibition of the key signaling pathway involved in fibrosis, the Transforming Growth Factor-beta (TGFβ) pathway [1] Key Product Information - The core candidate drug, ontunisertib (AGMB-129), is a selective and potent oral small molecule inhibitor of ALK5 (TGFβR1), primarily aimed at treating Fibrostenotic Crohn's Disease (FSCD) [1]
美股异动 | AgomAb Therapeutics(AGMB.US)登陆美股市场 开盘跌超13%